have the to you taking Mike, and time you Great good here. us. you, morning, Thank to Thank everyone. join for
Lucid. of catching business time you the some side We things and for Veris on spent up
website. yesterday call a As call on you call did is Lucid know, and we that -- do our
-- the focus of So, more on I'll and Veris. limit Lucid my topics
But with some recent let's start highlights.
Cancer example is Veris having adopter I'll early practices. how platform care the of impact. give Care the an impacting at side, it's Veris On that
early the development that's next-generation in will of and the launch fourth a version quarter. platform have under We
We goal President, leadership our team a the revenue commercial the are expanding accelerating half. under our enrollment of in of and restructuring with second subscriptions new Manning, patient and Gary from
portion his focuses as two that building that is a serve more novel and -- expand a initiatives device to clinical FDA One with in arrival. progressing will FDA on platform a the which added on new companion into support. its software commercial are medical planned upgrading clinical biopharma that's submission for for cancer XXXX, to module We've will heading and digital well, project allow of platform the functionality platform that serve our in strategic We're we more implantable monitor a towards decision therapeutics, later. as The as XXXX. to us also since launch is submission
Lucid from yesterday, in Again, the more from highlights some the details of but things. webinar side
at an XX% growth made volume payments Our we into six yesterday, upgraded highlighted an like quarter-on-quarter. revenue we inflection and We revenue as first infrastructure claims Really quarterly immediate volume translating we're cycle that's feel with weeks had transition. to on test both our provider, impact the that test since management, revenue. grew in regard and point and already growth
our the and We highlighted and an that offers contract, milestone for highlighted which we enrollment first submitted employee that EsoGuard publication have utility two employer study be results unprecedented released recently, soon. reached clinical as direct was prospective will studies from We funded benefit. first that NCI executed EsoGuard
and sectors: who to in the all story. and step digital of familiar Let company. have PAVmed of is an as health. PAVmed with operate medical you not me diagnostics devices, are technology a diversified those just slides a three couple back commercial-stage introduction We
Health, publicly-listed privately-held the pre-cancer. Diagnostics, course, vascular detection company, that is we esophageal of care a focus year, of company port. business. represent of smart a health the of as subsidiaries beginning structure of Lucid digital the this early Veris with And Nasdaq entirety a the have corporate is Our platform which on majority-owned of cancer two and our focused
again, with Veris. start let's So
digital a company. stage Veris So, health is commercial
care. on well mission to So, is commercialized physiologic which patient establishing longitudinal tools is The care are two management. in VerisBox the commercialize focused risk expect data through modern actively enhancing clinician There patient we're personalized components, patients which remote trends their physicians. a a transmit branded portal smartphone devices a from next to consists monitoring cancer to platform to we complications detection one module of one and year. Care Cancer that's to and married improve as the to of and utilize early of as The
model. model is revenue recurring a business Software-as-a-Service The
established We code. have RPM
on this Model, or We seek to Enhancing So leverage clinical the hurdle technical and also ERM. oncology, opportunities reimbursement us. additional enhanced are particularly models, are significant available. Oncology implantable for that There for support like the not is revenue a certain device focused when support, becomes ones value-based of
So, had putting platform on on we several These the generally and adopters. platform. that to execution are small commercial on are practices early the side, patients the medium
with going their the more -- and streamlining billings. the focus operations, their quite for making -- that health integration Our in well. within all efficient to last quarter electronic this customer has is processes And within of for integrate practices been support, the record
some used our the fourth by incorporate the received into have early part feedback which features platform, will and under have next-generation positive of to launch quarter. now right of development feedback is and that We actively
this second our expansion commercial in Manning, taken commercial half We do revenue are the has of expanding and lead again, the from we drive subscriptions. And and team. on to that. so restructuring to year Gary the look
way impact real as the thought remote that how save and it's particular works adverse with that I patient shows highlight yesterday having that can to describe system prevent patient best and did I'd that and it's on the I Lucid Care. That's -- that Cancer example monitoring one lives. outcome an
at XX-year-old in he risk client in was had a be to oncology Veris the male, selected unfortunately, aggressive He's a complications. diagnosed Dave, a with systemic Veris cancer. who's practice He duct patient, was high Southeast platform a that there's on given bile So treatment, of enrolled Pennsylvania. undergoing
as So can right the smartphone. and on see was devices the Bluetooth on the he platform monitoring connected the his with you loaded here, VerisBox received,
as changes as either Veris we So system patient symptom a the really, detected reporting abnormalities, are a that their morning platform highlight physiologic through sentinel see the allows on or the through to devices. that
that belly self-reported patient his the So, hurt.
on a on next sophisticated noted that a like time symptom the The can nurse rate the day you. you would how do period, see has a would that just ask the screens of platform. that it, quite there, has -- on one You the right he nurse physician or reporting
noted symptom, This and that's can moderately symptoms two, She -- red heart actual You of were bottom her. see belly noted reported also oxygen patient. rated that that pain, the to the is the there way example rate circle shows he little as severe. he changing concerning a that it the saturation in a from reported that the and there. he that She that was
You down. can oxygen rate see saturation heart green the for green the lines for going lines and going the the up
the that told was a would via would symptom the the her contacted that in the that be system. necessitate discharged. the be on So, acute triggers, to he progression into he but this hospital could bowel obstruction, telemedicine patient treated She Based direction next enough short education, in assessed and imminent built process early in did but was was thresholds room. that's in that emergency, symptoms potentially that and through patient. was the an heading the stay assessment hospital to and it She the and given the day, stent educated a the progress get wasn't the terms heading non-surgical an him she admitted fortunately, portal with emergency steps, patient who's what of patient on serious with he including a room, it rapidly the and that the diagnosed later in emergency those
surgery So have high-risk surgery. halted prevented he also death. cancer patients had warning potential any very in complication he really, intervention the surgery, platform the example an perforation, of from cancer healed had likely And a required and prevented potentially these how to -- is been high-risk care. progression a work therapy. this flawlessly early then until in classic If would treatment actual and emergency and it it The enhances delay of all
example preventing We programs complications, source of practice that save depend the the the there that like also have how hospitalization it income the this hospitalizations of DRG good shortening in And value major very notification early and drives and by estimated of payers also getting code they on EOM, occur. or based $XX,XXX income I no these solid the physicians. for the treatment infusion on a Also, mentioned the of the do this system is practices, documentation the between $XX,XXX value-based that expenditures, that loss and hospital hospital, therapy of complication. was for stays preventing is the
clearly, So the been on an contributor have calculations. would had to that a EOM this valuable and impact
As as I starting President, about and are with excited Manning mentioned, two we're we initiatives have Gary that coincident new both. really
focuses what is include Veris module calling is platform to therapeutics. on the currently a one And to expand companion that platform. digital we're first The a the here biopharma idea biopharma
the So, therapeutics linked cancer be provide solution patient monitoring solution. with we'll and target And monitoring long-term a novel to this patient developing are biopharma will companies that them tightly therapeutics.
will stage during monitored the in continue clinical So, these be again where have therapies, the it patients during can over And start significant clinical early approval companion The will analogy which the quite common early will that diagnostics. complications. common become something way and which that the full and half, all are through regulatory a has last decade the is commercialization. is and here trial
a [incidentally] therapeutic for during linked as linked regulatory to term. well and both development a clearance or they long during drug as we're become test, biologic So, the the (ph) diagnostic
opportunity enhancing reducing and So, for support post-marketing includes here providing adverse surveillance, clinical safety trials events. the by
previous and an of and filings, expedited monitored on more companies the long-term also complete -- trial. speed to different commercial the useful That therapeutics FDA to patient prevent clear commercial able partnerships as And we saw revenue has be trials during example the lower these accelerating that hurdles, with that expansion, source contingent it's has like complication were the clear regulatory entirely to as complications, devices, to clearance an market new being likely the for patients. see we business companies. the model. So, opportunity these to these monitoring it will different they in entirely and just regulatory the biopharma with would with the and lead of their That expectations to
Next slide.
from strategic a getting important software-as-a-medical transition of started Veris -- device. other quarter this The the our is initiatives on that platform we're to
Right data system. device two medical considered FDA software now, the a the Veris used healthcare categorizes So, in primary in platform is ways.
where that based allows the this sense hurdle. does it see medical saw rate on was it that, it. So, provided we all we threshold there's we or clinicians but -- with color the decision-making a and displays example that heart it built-in nurse saturation, on coding, to clinicians oxygen is no didn't but provide, analysis we for lower the high that the the Again, -- saw that and based and alert operate goes into regulatory to us under a data
For and something patients, treating -- additional its software-as-a-medical use active and -- actually a intended device, be it's support clinical it in could decision-making. provides clinical for diagnosing
clinical happen a unlimited that into us that So, what it grow to program MDDS provide is support with foundation platform full-bore to will And platform establishing launch we've potential software-as-a-medical the we're a device. a FDA-cleared to from tool. upgrade going decided to will a decision Veris after
patients biomarkers So, medical top threshold that effective algorithms list able of which, already, at to blue clinicians, and instead provide we'll ones have triage, various called is calculated the provide based for machine seen valuable, used alerts, will area be to where patient for complications to and and we've been at risk models simply be sophisticated course, alarms, algorithms, ocean a are displaying the heuristic learning profiling. more digital of for AI the so of data, be risk having that on greatest whole
to that make we're looking that, forward growing in all for do that order software-as-a-medical it And those to device. be we horizons have So into. transition are to to exciting
XXX(k) -- steps key next as year. So next to this incorporating are we'll initiating once allow are testing key FDA the that validation product initial launched, in us we to initiating support be device next-generation so, is -- will do and generation software-as-a-medical a be steps the submission features we'll
So we're looking that on. forward a initiative really exciting
update implantable the Final on monitor.
of power a recall, compliance this ensure extend you monitoring and remote If is the patient XXX% to billing the requirement. platform with
parameters, the Just patient at to a monitoring saturation, weight, reminder, as the measure blood a it, month. et for with and order codes XX has patient the actively remote pressure, in various cetera, for to the go physician least days practice oxygen
XXX% that compliance it will that With or device, patient threshold. depend RPM on the with that implantable billing a does not the guarantee compliance
consists So, this an implant, implantable monitor. of an
bottom development there of it occurred the could them an snap We've off-the-shelf on see allows that to multiple physiologic kind and implanted a rate parameters, going as and features event chemo can over feedback submission right existing the the activity. various [indiscernible], and same to year. be to time our that the with cardiac Bluetooth that's That's You port, in, have chemotherapy. there to quarters. and stand-alone be which allows commercial FDA to the correlated of next It It'll of and work will meetings seek and monitor has actual launch where engineering monitor their initiation to couple purple features has pre-submission FDA variety at last have continuous the smartphone. respiratory having that R&D symptom with a we're partners, the a connectivity very monitoring full temperature, have the on looking concur that well a an will manufacturing as design two had target measure the all patients of successful item
that's with Veris. it So,
Just at key diving and EsoGuard yesterday. -- portion two show and high-volume we of quarter-on-quarter slides firefighter as performed and spend continuing time to Again, into the we double-digit detail that tests the events elsewhere. quick testing be last X,XXX steady more more departments real them that nice to highlight some want growth volume points very we accomplishments the And in a testing to quarter. significant of -- in
results server. Institute. the been It's in is Cancer the PAVmed of a available funded recently centers a wanted The medical leading It area posted the disease, results study. to results of the compared for detected estimated highlight were on and centers esophageal This has have you an review when and of any the need to overall, be which The that American XX%, order National of study BETRNet negative gold of medical EsoGuard, consortium predictive preprint peer just I academic Also, to submitted the the of results with that is not on test positive by missing -- was to a of been released. academic XX% is that the threshold in make XX% value both effective you're cancers, Gastroenterology. pre-cancers an sure to patients. endoscopy, of the Journal XXX% demonstrated that standard --
that really these as standards detection highlight early imminent other to results results the I -- or attention us comparison relative and relative for successful are -- for other these of but are performance head-to-head of a tests. these a those other cancer lot what getting they targets, what what the not have is they what tests to target targets are suggested for directly, highlight successful been really to
even results. deemed as substantially for in The colorectal but at achieve as see, clearance, payment is Cologuard than test Medicare. above, as Guardant to and where XXX% the newer lower you to cancer the from that, can sufficient are blood so, we still FDA range be And well frankly, for in it detection, well reported
that ability were up we the that, cancers quite by its Although note for all really, unprecedented, that I rate The highlight to XX%. is of is XX% heavily important of this poor that Stage the most is EsoGuard cancers described picked and the later-stage per that is I'll BETRNEt -- detect cancers. number striking dominated in Stage all cancer is difference at the this study where pre-cancer. EsoGuard's ability as I and
doing ability have so So, than essentially meaningful pre-cancer, while range. no EsoGuard the blood at XX% detect Cologuard greater the test, XX% to just under does is of
Stage reasonable, have pick because colorectal option. is esophagus cancer cancer to don't Stage that can We curable. for an for cancer, But that for cancer, Now be very high. and esophageal up very, I mortality in rate the we have I is pre-cancer actually
over that, to at it baton leave Dennis. hand to I'll So, and the
